Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

Janice Chen

Trevor Martin

Jennifer Doudna

Ashley Tehranchi

Lucas Harrington

Mammoth Biosciences

Biomatter develops proteins and enzymes with Intelligent Architecture™ for health and sustainable manufacturing. The company provides solutions from initial concept to protein production.

Biomatter

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

National Institutes of Health

aMoon Fund

Decheng Capital

Verily

Pacific 8 Ventures

Plum Alley Investments

Mayfield Fund

Brook Byers

Senator Investment Group

Foresite Capital

Greenspring Associates

Sixth Street Partners

Tachyon Ventures

Redmile Group

Bradley Horowitz

Don’t miss this tutorial session with Agilent Technologies and Mammoth Biosciences! Join us for an informative afternoon, our own Wesley Addison will be presenting.
See you there! #Innovation #Science #TechTalk #Biotech

Today at Keystone Symposia on Molecular & Cellular Biology's Precision Genome Engineering conference, Mammoth Biosciences co-founder & CTO Janice Chen will present an update on “Developing in vivo Therapeutics with Ultracompact CRISPR Systems”. The talk will highlight our fundamental innovation on #ultracompact #crispr  cargo and progress towards unlocking in vivo delivery of next-generation gene editors beyond the liver.

We're #hiring a new Vice President, Technical Operations in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Vice President, Translational Sciences in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Principal Project Manager I - Drug Development/Therapeutics in Brisbane, California. Apply today or share this post with your network.

Jenny is an amazing leader that if you qualify for the role, you should apply.

Metric
Company Name	Mammoth Biosciences	Biomatter	CRISPR Biotech Engineering	Ginkgo Bioworks Holdings, Inc.
Symbol				DNA
MSH ID	BIO:MAMMOTH	COM:BIOMATTER	COM:CRISPR-BTE	COM:GINKGOBIOWORKS
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Technology	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	LT	GB	US
Stage	Series D			Grant
Employee Count	185			1.22K
Website	mammoth.bio	biomatter.com	crispr-bte.com	ginkgobioworks.com
LinkedIn	mammothbio	biomatter		ginkgo-bioworks
Founders

Metric
Market Cap		725.64M
Enterprise Value
Monthly Web Traffic	6.85K	20.69K
Web Traffic Growth	-0.30	-0.17
Valuation
Raised Capital	150M

Metric
Revenue				251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit				142.64M
EBITDA				-600.68M
Operating Income				-672.23M
Net Income				-892.87M
EPS				-0.46
Diluted EPS				-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.75
Operating Profit Margin				-3.34
EBITDA Margin				-2.39
Net Profit Margin				-3.55
Return on Equity				-0.65
Return on Assets				-0.54
Return on Capital Employed				-0.51

BIO:MAMMOTH

Mammoth Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-2.78
P/B Ratio				1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				93.70
EV Multiple				-1.34

Metric
Days Sales Outstanding				73.17
Days Payables Outstanding				50.57
Days Inventory Outstanding				0.27
Operating Cycle				46.33
Cash Conversion Cycle				-7.39
Asset Turnover				0.15

Metric
Operating Cash Flow				-295.50M
Free Cash Flow				-336.30M
Cash Flow to Debt				-0.63
Operating Cash Flow/Sales				-1.14
Free Cash Flow Yield				-0.16

Metric
Cash & Equivalents				948.86M
Accounts Receivable				50.07M
Inventory				46K
Goodwill				49.24M
Debt to Capitalization				0.35
Debt to Assets				0.20
Current Ratio				6.78
Quick Ratio				5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.94
R&D to Revenue				2.05
SG&A to Revenue				1.32